NICE ‘fast-tracking’ underlines threat from BMS/Pfizer’s Eliquis to Pradaxa and Xarelto
This article was originally published in Scrip
Executive Summary
The positive reimbursement decision from NICE on 23 January means that Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) means will likely start competing with Boehringer Ingelheim's Pradaxa (dabigatran etexilate) and Bayer's Xarelto (rivaroxaban) in stroke prevention as early as next month, February 2013. Datamonitor analyst Victoria Hudson, says Eliquis will compete well against its rival novel anticoagulants even in a market where uptake of warfarin-replacements has been slower than expected.